Skip Navigation

Key Eligibility Criteria for CAR T-Cell Therapy for Lymphoma

  • Key eligibility criteria include:

    • Confirmed diagnosis of DLBCL, primary mediastinal large B cell lymphoma, high grade B-cell lymphoma, or transformed follicular lymphoma to DLBCL that has either not responded to first line chemotherapy, not responded to second or greater lines of chemotherapy, or relapsed within 12 months of an autologous stem cell transplant. Therapy must have included an anti-CD20 antibody and an anthracycline.
    • Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures).

    Patients must have a referral from their oncologist to DF/BWCC's Adult Lymphoma Program to be evaluated for CAR T-cell therapy.

  • Caron Jacobson, MD, at a computer


    Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).